NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+0.17%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$2.25B
AUM Growth
+$2.25B
(-6.9%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
0.57%
Top 10 Holdings %
Top 10 Hldgs %
64.56%
Holding
59
New
8
Increased
8
Reduced
13
Closed
5
Top Buys
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
$54M |
| 2 |
Inogen
INGN
|
$44.3M |
| 3 |
Cable One
CABO
|
$41M |
| 4 |
Praxis Precision Medicines
PRAX
|
$28M |
| 5 |
EAR
Eargo, Inc. Common Stock
EAR
|
$20M |
Sector Composition
| 1 | Healthcare | 61.05% |
| 2 | Financials | 7% |
| 3 | Technology | 6.3% |
| 4 | Consumer Discretionary | 2.54% |
| 5 | Communication Services | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$526B
| $431M | 19.11% |
1,933,900
| – | – |
|
2
Brookfield
BN
$98.3B
| $157M | 6.95% |
3,075,079
+4,122
| +0.1% | +$210K |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $152M | 6.73% |
2,645,446
| – | – |
|
4
Apple
AAPL
$3.45T
| $142M | 6.3% |
1,037,404
| – | – |
|
|
5
Inogen
INGN
$216M
| $136M | 6.01% |
2,079,320
-680,000
| -25% | -$44.3M |
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $119M | 5.29% |
5,587,207
| – | – |
|
|
CYT
7
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $104M | 4.59% |
+4,840,413
| New | +$104M |
|
8
Nkarta
NKTX
$151M
| $88.5M | 3.93% |
2,793,864
| – | – |
|
9
Bolt Biotherapeutics
BOLT
$9.85M
| $69.6M | 3.09% |
4,503,991
| – | – |
|
10
Alibaba
BABA
$322B
| $57.3M | 2.54% |
214,827
| – | – |
|
11
Aligos Therapeutics
ALGS
$73.3M
| $53.3M | 2.36% |
2,614,563
| – | – |
|
|
SPRB
12
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $50.6M | 2.24% |
4,514,336
-475,000
| -10% | -$5.32M |
|
|
13
Cable One
CABO
$909M
| $49.5M | 2.2% |
25,898
-21,443
| -45% | -$41M |
|
|
VERV
14
DELISTED
Verve Therapeutics
VERV
| $47.8M | 2.12% |
+793,265
| New | +$47.8M |
|
15
Mirum Pharmaceuticals
MIRM
$3.71B
| $42.3M | 1.88% |
2,445,147
| – | – |
|
|
VECT
16
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $41.1M | 1.82% |
+3,522,019
| New | +$41.1M |
|
|
17
Harmony Biosciences
HRMY
$2.12B
| $40.2M | 1.78% |
1,422,953
-1,913,425
| -57% | -$54M |
|
18
LAVA Therapeutics
LVTX
$41.3M
| $36.2M | 1.61% |
3,327,312
| – | – |
|
|
OKUR
19
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $32M | 1.42% |
+3,430,377
| New | +$32M |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $31.8M | 1.41% |
1,867,706
-101,673
| -5% | -$1.73M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $26.9M | 1.19% |
600,010
-267,714
| -31% | -$12M |
|
|
GRTX
22
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $24.2M | 1.07% |
2,459,021
| – | – |
|
|
SPNE
23
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $22.8M | 1.01% |
1,113,846
-207,160
| -16% | -$4.25M |
|
24
Insmed
INSM
$28.8B
| $19.8M | 0.88% |
695,840
+239,209
| +52% | +$6.81M |
|
25
Amicus Therapeutics
FOLD
$2.34B
| $19.3M | 0.85% |
1,997,880
+35,000
| +2% | +$337K |
|